Logo

454 s Q1 Revenue Surges, Though Grant Receipts Slip 29 Percent

Apr 27, 2006

NEW YORK, April 27 (GenomeWeb News) - 454 Life Sciences generated $8.8 million from sales of instrument and reagents, fee-for-service sales, and milestone and royalty payments, up from $1.3 million year over year

 

The majority-owned CuraGen subsidiary also said revenue from grants slipped 29 percent in the period to $500,000 from $700,000 year over year.

 

Breaking down the numbers for this period, CuraGen said 454 generated nearly $4.5 million in product sales while the 454 SequencingCenterbrought in approximately $2.4 million.

 

In its statement today, CuraGen did not disclose 454's figures from the first quarter 2005; the information was obtained from CuraGen's website.

Breaking News
The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.